Table 3.
Association between irAEs and treatment responses.
| All (n = 231) | With irAE (n = 93) | Without irAE (n = 138) | p-value | |
|---|---|---|---|---|
| CR, n (%) | 5 (2) | 4 (4) | 1 (1) | |
| PR, n (%) | 69 (30) | 41 (44) | 28 (20) | |
| SD, n (%) | 51 (22) | 22 (24) | 29 (21) | |
| PD, n (%) | 96 (42) | 19 (20) | 77 (56) | |
| NE, n (%) | 10 (4) | 7 (8) | 3 (2) | |
| ORR, n (%) | 74 (32) | 45 (48) | 29 (21) | <0.001a |
| DCR, n (%) | 125 (54) | 67 (72) | 58 (42) | <0.001a |
Differences between groups were identified using achi-square test. IrAE, immune-related adverse event; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable; ORR, objective response rate; DCR, disease control rate